ArticleBMC cardiovascular disorders2026
Survival and mortality predictors among adults with rheumatic heart disease in ethiopia: a 10-year retrospective cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatic heart disease (RHD) remains highly prevalent in low-income countries and is associated with severe complications and premature mortality. Limited local evidence in Ethiopia hinders understanding of disease progression and risk stratification. This study aimed to assess patterns of complications, survival, and predictors of mortality among adults with RHD in Ethiopia.
methodsWe conducted a retrospective cohort study of 1,811 adults (≥ 18 years) with definite RHD diagnosed by transthoracic echocardiography according to the 2012 World Heart Federation criteria. Patients received care at the Cardiac Center of Ethiopia between January 1, 2015, and January 1, 2025. Complications and mortality were summarized descriptively. Survival was estimated using Kaplan–Meier methods and compared with log-rank tests. Independent predictors of mortality were identified using multivariable Cox proportional hazards regression.
resultsThe median age was 32 years, with a female-to-male ratio of 1.5:1. Over a median follow-up of 5 years (IQR 2.5–6.5), 1,037 participants (57.3%) developed at least one complication, most commonly New York Heart Association (NYHA) class III–IV heart failure with pulmonary hypertension (31.4%) and isolated pulmonary hypertension (19.8%). A total of 326 participants (18.0%) died, with significantly lower survival among those with complications (p < 0.001). Independent predictors of mortality included presence of comorbidities (AHR 5.8), increased left ventricular internal diastolic diameter (LVIDd) (AHR 2.1), monthly income < 2,000 Ethiopian birr (≈ 13 USD) (AHR 1.2), NYHA class III–IV heart failure (AHR 2.2), and pulmonary hypertension (AHR 2.4).
conclusionAdults with RHD in Ethiopia experience high rates of complications and premature mortality, driven by advanced heart failure, pulmonary hypertension, ventricular dilation, comorbidities, and socioeconomic disadvantage. Early detection, optimized chronic disease management, and expanded access to surgical and percutaneous interventions are urgently needed to improve outcomes in this resource-limited setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.